Contineum Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2023 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Contineum Therapeutics, Inc. quarterly Operating Income (Loss) history and growth rate from Q1 2023 to Q3 2024.
Contineum Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$13M, a 60.8% decline year-over-year.

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024		-$13M	-$4.91M	-60.8%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-06
Q2 2024		-$10.9M	-$49.9M	-128%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-14
Q1 2024		-$9.93M	-$4.82M	-94.1%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-16
Q3 2023		-$8.07M			Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-06
Q2 2023		$38.9M			Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-14
Q1 2023		-$5.12M			Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-16

* An asterisk sign (*) next to the value indicates that the value is likely invalid.